VION will suspend enrollment and further patient treatment in its Phase III clinical study of Cloretazine for patients with relapsed adult myelogenous leukemia pending a detailed review of all of the data from the trial.
Ads by Google
Drug Clinical Trials
With the help of biomarkers and Philips' advanced non-invasive medical imaging technology, it will for example be possible to study the effects of psychiatric drugs in the brain at the molecular level.
Boston Scientific Corporation welcomed the results of data from the SPIRIT FIRST, II and III Clinical Trials, reaffirming prior safety and efficacy data for TAXUS Express2 Paclitaxel-Eluting Coronary Stent System and XIENCE V Everolimus Eluting Coronary Stent System.
Principal investigators for the COSTAR II (CObalt Chromium STent with Antiproliferative for Restenosis) trial confirmed that the study failed to meet its primary endpoint.
Intarcia Therapeutics presents results from a Phase 2 study comparing the combination of injectable omega interferon and ribavirin to omega interferon alone in treatment-naive patients with genotype 1 chronic hepatitis C.
MIGENIX will make a presentation of results from a recent hepatitis C Phase II combination therapy study.
Manhattan Pharmaceuticals Completes Dosing Portion Of Two Phase 2a Clinical Trials Of Oral Oleoyl-Estrone For Obesity
Manhattan Pharmaceuticals announced it has successfully completed patient dosing in two separate, ongoing Phase 2a clinical trials of oral Oleoyl-estrone.
Catalyst Pharmaceutical Partners announced positive initial, top-line results from a bioequivalence study demonstrating that CPP-109 (Catalyst's Vigabatrin Tablets) is bioavailable and bioequivalent to Sabril Tablets, the version of vigabatrin marketed in Europe by Sanofi Aventis.
WHO launched a new web site that will enable researchers, health practitioners, consumers, journal editors and reporters to search more easily and quickly for information on clinical trials.
Isotechnika Inc. will announce interim three month data from its Phase 2b kidney transplant trial for the Company's lead immunosuppressive drug.
New Phase II study results show Abbott's investigational treatment, ABT-874, reduced psoriasis symptoms significantly in the majority of patients treated.
Thoratec Corporation said that the FDA has approved an Investigational Device Exemption supplement that allows enrollment of up to an additional 60 patients in the Bridge-to-Transplantation arm of the company's HeartMate II Phase II trial under a Continued Access Protocol.
Marinus Pharmaceuticals announced that it is enrolling patients in an international, multi-center, placebo controlled Phase IIb study of its lead compound, Ganaxolone, as an adjunctive treatment in adults suffering from partial onset seizures.
Sequella announced the results of its tuberculosis drug SQ109 Phase 1a clinical trial.
Spectrum Pharmaceuticals announced that it has initiated its pivotal Phase 3 registrational trials for EOquin, the Company's proprietary drug candidate for non-invasive bladder cancer.
Spectrum Pharmaceuticals announced that the Company has reached its enrollment target in the Phase 2b trial of ozarelix in patients suffering from benign prostatic hypertrophy (BPH).
VioQuest Pharmaceuticals announced that it will proceed with Phase II trials later this year with its direct Akt inhibitor VQD-002.
Access Pharmaceuticals has continued to expand the number of clinical trial sites for its on-going Phase 2 trial of ProLindac in patients with recurrent platinum-sensitive ovarian cancer.
Further investigation revealed that seven of the 17 bottles of syrup medicine claimed or labeled as "terbutaline" and were seized from the clinic of a private medical practitioner in Tuen Mun contained isopropyl alcohol.
Medical professionals conducting clinical trials should be provided more information about financial conflicts of interest before they talk to patients about participating in the trials.
Alimera Sciences, a privately held ophthalmic pharmaceutical company, and global drug delivery company pSivida Limited announced that enrollment for their Phase 3 global clinical trial, the FAME (Fluocinolone Acetonide in Diabetic Macular Edema) Study has exceeded 50 percent.
Under the order of the United States Anti-Doping Agency Paul Scott was denied entry to the Laboratoire National de Depistage du Dopage at Chatenay-Malabry.
Interim Results Presented at EASL from PROVE 1 Clinical Trial of Investigational Drug Telaprevir in patients with Genotype 1 Hepatitis C. PROVE 1 data support potential to shorten treatment duration in treatment-naive, genotype 1 HCV patients.
Rush University Medical Center To Conduct Phase III Clinical Trial Of Creatine For Parkinson's Disease
Rush University Medical Center will participate in a large-scale national clinical trial to learn if the nutritional supplement creatine can slow the progression of Parkinson's disease (PD).
The interim data presented at EASL suggest that Albuferon may offer efficacy at least comparable to peginterferon alfa-2a, with half the injections and the potential for less impairment of quality of life.
The Department of Health announced an agreement that will enable approved industry-sponsored clinical trials to start sooner in NHS Primary Care.
Intarcia Therapeutics Announces Results From Phase 2 Study Of Injectable Omega Interferon Plus Ribavirin
Intarcia Therapeutics Inc. announced final results from a Phase 2 study of omega interferon with or without ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.
Oncolytics Biotech Inc. announced that subsequent to the regulatory review period for this submission, it is proceeding with a Phase II trial to evaluate the intravenous administration of REOLYSIN in patients with various sarcomas that have metastasized to the lung.